- Verastem press release ( NASDAQ: VSTM ): Q2 Non-GAAP EPS of -$0.11 in-line.
- Verastem Oncology ended the second quarter 2022 with cash, cash equivalents and investments of $94.3 million. With proceeds available upon achievement of certain milestones from the Oxford Finance LLC credit facility and expected milestones and royalties from the sale of COPIKTRA, Verastem Oncology expects that it has a cash runway until at least 2025 to deliver on the current programs for VS-6766 and defactinib, including expenditures and development in LGSOC and KRAS mutant NSCLC.
- Shares +2.52% PM.
For further details see:
Verastem Non-GAAP EPS of -$0.11 in-line